{
  "figure_1": "Schematic representation of an antibody-drug conjugate",
  "figure_2": "Mechanism of action of antibody-drug conjugates",
  "figure_3": "Chemical structures of disclosed drug-linker moieties used in antibody-drug conjugates against HER2-positive breast cancer",
  "figure_4": "Antibody, payload, and linker types\nTypes of antibody (A), payload (B), and linker (C)Â used in antibody-drug conjugates under development for patients with HER2-positive breast cancer in clinical trials. mAb, monoclonal antibody."
}